Related Experiment Video
Updated: Jan 31, 2026
04:30
A Murine Model of Stent Implantation in the Carotid Artery for the Study of Restenosis
Published on: May 14, 2013
26.3K
Drug-Coated Balloon Angioplasty for Femoropopliteal In-Stent Restenosis
Salvatore Cassese1, Florian Wolf2, Maja Ingwersen3
1Deutsches Herzzentrum München, Technische Universität München, Munich, Germany (S.C., G.N., I.O., Massimiliano Fusaro).
Circulation. Cardiovascular Interventions
|December 19, 2018
Summary
Drug-coated balloon (DCB) angioplasty significantly reduces target lesion revascularization and restenosis in femoropopliteal in-stent restenosis (ISR) compared to plain balloon angioplasty. This superior efficacy was observed across various high-risk patient subgroups at 12-month follow-up.
Area of Science:
- Vascular surgery
- Interventional cardiology
- Biomaterials science
Background:
- Optimal revascularization for femoropopliteal in-stent restenosis (ISR) remains debated.
- Drug-coated balloon (DCB) angioplasty is a potential treatment for ISR.
Purpose of the Study:
- To investigate the efficacy of DCB angioplasty versus plain balloon angioplasty for femoropopliteal ISR.
- To compare target lesion revascularization and recurrent ISR rates between DCB and plain balloon angioplasty.
Main Methods:
- Pooled patient-level data from 3 randomized trials comparing DCB and plain balloon angioplasty for femoropopliteal ISR.
- Primary outcome: target lesion revascularization. Secondary outcomes: recurrent ISR, amputation, death, Rutherford class, ABI.
- Analysis included 263 patients (133 DCB, 130 plain balloon) with 12-month follow-up.
Main Results:
- DCB angioplasty significantly reduced target lesion revascularization (HR 0.25; P<0.001) and recurrent ISR (HR 0.19; P<0.001) versus plain balloon angioplasty.
- No significant interaction between treatment effect and high-risk subgroups (diabetes, long lesions, calcification, etc.).
- Other secondary outcomes were comparable between groups.
Conclusions:
- DCB angioplasty demonstrates superior clinical and antirestenotic efficacy compared to plain balloon angioplasty for femoropopliteal ISR at 1 year.
- Efficacy of DCB angioplasty is maintained in high-risk patient subgroups.
- Long-term durability of DCB angioplasty in this setting requires further investigation.
More Related Videos
Related Concept Videos
01:32Pinching-off of Coated Vesicles
4.2K
Vesicle budding is orchestrated by distinct cytosolic proteins such as adaptor proteins, coat proteins, and GTPases. To initiate vesicle budding, membrane-bending proteins containing crescent-shaped BAR domains bind to the lipid heads in the bilayer and distort the membrane to form a protein-coated vesicle bud. Adaptors proteins such as AP2 for clathrin-coated vesicles can nucleate on the deformed membrane. Finally, coat proteins such as clathrin or COPI and COPII assemble into a coat forming...
4.2K
01:12Clathrin Coated Vesicles
9.4K
Clathrin-coated vesicles use endocytosis to transport receptors and lysosomal hydrolases from the Golgi to the lysosome in the late secretory pathway. Clathrin-mediated endocytosis was the first described endocytic process, and Clathrin-coated vesicles remain one of the most well-studied transport vesicles. The molecular machinery that generates clathrin-coated vesicles comprises over 50 proteins that precisely coordinate vesicle formation. Cell surface receptors concentrated in indented sites...
9.4K
00:59COP Coated Vesicles
18.2K
Membrane-enclosed structures called vesicles transport proteins and lipids across the cell. The vesicles derive their cargo from the plasma membrane, Golgi, ER, or endosome. Coated vesicles are spherical, protein-coated carriers with a 50–100 nm diameter that mediate bidirectional transport between the ER and the Golgi. The distribution of proteins between the ER and Golgi complex is dynamic and is maintained by different coated vesicles. Their formation is driven by the assembly of...
18.2K
01:33Coat Assembly and GTPases
4.4K
Vesicles incorporate different coat protein subunits in different cell locations, which changes the properties of the coat, such as the shape and geometry of the transport vesicles. Thus, vesicle coat proteins also play a significant role in cargo selection.
Coat assembly depends on the local availability of phosphatidylinositol phosphates or PIPs and GTP-binding proteins. Adaptor proteins, which link the coat proteins to the membrane, bind to these PIPs and play a crucial role in controlling...
Coat assembly depends on the local availability of phosphatidylinositol phosphates or PIPs and GTP-binding proteins. Adaptor proteins, which link the coat proteins to the membrane, bind to these PIPs and play a crucial role in controlling...
4.4K
01:25Pharmacokinetics: Drug–Drug Interactions
440
Drug interactions occur when the pharmacological effect of one drug is altered by another substance, either enhancing or diminishing its activity. The drug whose activity is altered is known as the object drug, and the substance causing the alteration is called the agent drug or the precipitant. The net effects of these interactions are mostly undesirable, leading to decreased effectiveness or increased adverse effects. In rare cases, interactions can be beneficial, such as the enhanced...
440
01:09Bioequivalence of Drugs: Drugs with Multiple Indications
158
The concept of therapeutic equivalence (TE) in drugs with multiple indications is complex. A generic drug may be therapeutically equivalent to a brand-name product for one specific indication, but this doesn't necessarily mean it's equivalent for all other indications. Evidence of TE in one patient group and bioequivalence shown in healthy volunteers can support—but not confirm—TE for other indications. However, definitive proof requires individual clinical studies for each...
158